No Data
Express News | Shares of US-listed Chinese Companies Are Trading Lower Amid Global Investor Concerns Regarding the Trump Administration's Trade Policies and China's Retaliatory Tariffs on US Farm Goods, Which Took Effect Monday
Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
US stocks movement | LexinFintech (LX.US) rose by 15.41%, with digital finance driving high-quality Business growth.
Since the beginning of the year, stock prices have repeatedly set historical records.
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Qianxin Biotechnology-B (02509.HK): The supplemental application for QX001S (LexinFintech, ustekinumab injection) for pediatric plaque psoriasis has been approved.
On March 3, 2023, Glonghui announced that Chuanxin Biology-B (02509.HK) received the "Approval Notice for Supplementary Application for Pharmaceutical" issued by the National Medical Products Administration (NMPA) on March 3, 2025. The supplementary application for QX001S, which adds the indication for pediatric plaque psoriasis, has been approved. QX001S is a biosimilar of the original product Stelara (ustekinumab injection), and its mechanism of action is to block the binding of the shared p40 subunit of IL-12 and IL-23 to the IL-12Rβ1 receptor protein on the surface of target cells, thereby inhibiting.
CICC: AI + finance is expected to迎来 a scaling inflection point.
The equalization of AI technology continues, and the financial IT Industry has clear enabling scenarios, with the potential to achieve a transition from "tool empowerment" to "Asia Vets restructuring."
